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Abstract
Recent morphologic and molecular genetic studies have led to a paradigm shift in our conceptualization of the
carcinogenesis and histogenesis of pelvic (non-uterine) serous carcinomas. It appears that both low-grade and
high-grade pelvic serous carcinomas that have traditionally been classified as ovarian in origin, actually originate, at
least in a significant subset, from the distal fallopian tube. Clonal expansions of the tubal secretory cell probably
give rise to serous carcinomas, and the degree of ciliated conversion is a function of the degree to which the
genetic hits deregulate normal differentiation. In this article, the authors review the evidentiary basis for
aforementioned paradigm shift, as well as its potential clinical implications.
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Worldwide, approximately 225,500 women are diag-
nosed with ovarian cancer annually, with an estimated
140,200 associated deaths [1]. Although ovarian cancer
accounts for only 3% of all cancers in women, it has one
of the highest death-to-incidence ratios, which has been
primarily attributed to the unavailability of effective
screening tools, the absence of early phase symptomatol-
ogy in many patients, and accordingly, its typical presen-
tation at advanced stages when prognosis is poor [2,3].
As has become apparent in recent years, one of the
greatest obstacles to the detection of early-stage ovarian
cancer was our poor understanding of its histogenesis
and pathogenesis. Ovarian carcinoma was traditionally
thought to originate from the ovarian surface epithelium
(OSE) or ovarian epithelial inclusions (OEI), and investi-
gative efforts at early detection have accordingly been
centered on the ovary for decades. However, these
efforts have not been successful, as evidenced by the
fact the overall survival for women with ovarian cancer
has not changed in any fundamental manner over the
last 50 years [4]. Several emerging lines of evidence indi-
cate that some traditional tenets of ovarian epithelial
carcinogenesis and cellular origination are fundamen-
tally flawed.
Patients with high-grade serous carcinoma (which con-
stitute 60-80% of ovarian epithelial carcinomas [OEC], and
which represent the archetypical “ovarian cancer”) most
frequently present at advanced clinical stage and have a
very poor overall survival [5,6]. Therefore, understanding
of the nature and development of this type is extremely
important for improving the survival rate of ovarian can-
cer patients as a group. Recently, studies of both asympto-
matic women with germline BRCA1 or BRCA2 mutations
as well as those from the general population with pelvic
serous carcinoma, have detected precancerous or early
cancerous lesions - serous tubal intraepithelial carcinoma
(STIC) - in the fallopian tubal fimbria [7-9]. Furthermore,
a spectrum of potential precursor lesions to serous carci-
nomas, including the ‘p53 signatures’ and the ‘secretory
cell outgrowth’, have similarly been described in the fim-
bria [10,11]. From those and other studies, the fallopian
tube has emerged as an important potential source for
female pelvic serous carcinomas, resulting in a paradigm
shift that will likely have important implications for future
detection, therapy and prevention in ovarian cancer. This
review will discuss the recent advances in the field of ovar-
ian or pelvic serous histogenesis and carcinogenesis, as
well as the potential clinical applications of these advances.
Dualistic model of serous carcinoma
Based on morphologic, immunohistochemical and mole-
cular data, a broader, dualistic model of ovarian
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carcinogenesis has been proposed that classifies ovarian
carcinomas into 2 groups: Type I and Type II. Type I
tumors include low-grade serous carcinomas (LG-SC),
low-grade endometrioid carcinomas, clear cell and
mucinous carcinomas, and Brenner tumors. Type I
tumors are not clinically aggressive, generally present at
early stage, rarely harbor TP53 mutations, but instead
display mutations involving specific cell signaling path-
ways, including KRAS, BRAF, ERBB2, PTEN, CTNNB1,
PIK3CA, ARID1A, and PPP2R1A. Type II tumors, which
include high-grade serous carcinomas (HG-SC), high-
grade endometrioid carcinomas, malignant mixed meso-
dermal tumors (carcinosarcomas), and undifferentiated
carcinomas, frequently display TP53 mutations and are
genetically unstable [12].
LG-SC is thought to develop in a stepwise fashion,
sequentially from OEIs or serous cystadenoma, then to
serous borderline tumor, and eventually to invasive car-
cinomas [13-15]. In contrast, HG-SC, the prototypic of
type II ovarian cancer, is a highly aggressive neoplasm,
and afflicted patients almost always present at an
advanced stage. HG-SC is characterized by high levels of
genetic instability, a very high frequency of TP53 gene
mutations, and low frequency of the molecular aberra-
tions that typify Type I carcinomas including KRAS and
BRAF mutations. Therefore, this dualistic model has
clinical, pathologic and molecular evidentiary support,
and provides a valuable framework for studying and
analyzing the larger subject of ovarian carcinomas.
Cell of origin of serous carcinoma
The origin of ovarian cancer has perplexed investigators
for decades. The more prominent theories that have
been preferred are discussed below:
The theory of OSE as origin of OEC and its
drawbacks
The hypothesis that OSE is the site of origin site for
OEC is based on relatively weak histological arguments,
its wide acceptance notwithstanding. The OSE, which is
continuous with the mesothelial lining of all pelvic
organs, bears no resemblance to OECs. Some studies
have showed that the OSE cell is an uncommitted
mesothelial cell, which has a phenotypic plasticity, as
demonstrated by its reactivity with antibodies indicative
of multiple lines of differentiation [16,17]. The OSE was
assumed to invaginate into the underlying stroma to
form OEI [16]. These inclusion cysts, with their newly
acquired müllerian phenotype (by metaplasia), could
then undergo malignant transformation resulting in car-
cinomas corresponding to the different cell types (ser-
ous, endometrioid, clear cell, mucinous and transitional
cell) [18].
The OSE theory for the genesis of OECs has a num-
ber of limitations. If one takes the point of view that
carcinomas arise from, or at minimum differentiate
towards, a cell type native to the organ in which the car-
cinomas arose, then the following three points are sali-
ent: 1) The normal ovary has no constituents that
resemble the OECs, and some biomarkers such as
HOXA and PAX8 are extensively expressed in OECs,
but not in OSE [18-20]. 2) OSE overlying the ovaries is
continuous with mesothelium lining of all pelvic and
abdominal organs. The OSE or mesothelium, is embryo-
logically distinct from Müllerian epithelia in general; 3)
A true precursor lesion of OECs has rarely, if ever, been
found in the ovaries; Although OEIs lined with ciliated
cells are frequently observed in the ovarian cortex, well-
documented examples of what can be interpreted as a
transition from these cystic structures to high grade car-
cinoma have not been reported. These simple observa-
tions are arguments against the theory that OEC
originate from the OSE with any significant frequency.
Secondary müllerian system theory
Some tumors that are morphologically identical to ovar-
ian carcinomas can occasionally be found outside the
ovary, even though the ovaries, or indeed the ovaries,
fallopian tubes and uterus, had previously been removed
[21-23].
Therefore, an alternate theory was proposed by Lau-
chlan [24], in which all of the Müllerian-type epithelium
found outside the primary Müllerian system (uterus,
cervix, and fallopian tubes) were termed as “secondary
Müllerian system”, including OSE, OEIs, paraovarian/
paratubal cysts, rete ovarii, endosalpingiosis, endome-
triosis and endocervicosis. Lauchlan proposed that all
tumors with a Müllerian phenotype (serous, endome-
trioid, and clear cell) in the pelvis are derived from
these müllerian-type epithelia either directly or by a
metaplastic process. This theory provided a straightfor-
ward explanation for the presence of ovarian-like
tumors arising outside the primary Müllerian system.
Lauchlan also proposed that endosalpingiosis, endocervi-
cosis, and endometriosis can evolve into one another
through metaplasia. Although it is still unclear what
conditions or factors promotes this transition from one
state to the other, metaplasia from endosalpingiosis to
endocervicosis or to endometriosis are commonly
observed in ovarian pathology [25]. Lauchlan’s visionary
hypothesis remains instructional in clinical practice and
ovarian cancer research. Additionally, the secondary
Müllerian system succintly explains why the epithelial
tumors in ovary and in pelvis are morphologically iden-
tical to those tumors within the primary Müllerian sys-
tem. However, it does not specifically address whether
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tumors that have traditionally been classified as “ovar-
ian” in origin may have an extraovarian origin.
The tubal theory: the fallopian tube as the site of
origin for “ovarian” high grade serous carcinoma
The fallopian tube has traditionally played a minor role
in female adnexal pathology. However, the past decade
has seen the emergence of a robust body of evidence,
including clinical-pathological and molecular findings,
that lend significant credence to the notion that “ovar-
ian” HG-SCs result from the a clonal expansion of the
secretory cells in the distal fallopian tube, rather than
the ovary [9,26-29].
Clinical-pathological evidence
Since most of ovarian carcinomas that are identified in
BRCA mutation carriers are HG-SCs, examination of
prophylactic salpingo-oophorectomy specimens should
theoretically reveal a precursor lesion in the ovary in at
least a subset of these patients. However, early serous
malignancies STICs have been found to involve the fallo-
pian tube, rather than the ovarian surface or within ovar-
ian cortical inclusion cysts. Piek et al were the first to
describe “dysplastic changes or tubal dysplasia”, which
was later described as tubal lesions in transition (TLIT)
[11,30] in the fallopian tubes in this setting. The authors
described lesions that closely resemble HG-SCs in the
fallopian tubes of 50% of a cohort of women with familial
high risk for ovarian cancer undergoing prophylactic sal-
pingo-oophorectomies [31]. There have now been
numerous subsequent studies, in which fallopian tubes
were more carefully examined, that confirmed the exis-
tence and incidence of STICs and early invasive tubal
carcinomas in BRCA mutation carriers that underwent
risk reducing salpingo-oophorectomy procedures
[7-9,32-38]. Based on these studies, early serous carcino-
mas in these specimens occur in between 2% and 17% of
cases and involve that fallopian tube mucosa up to 100%.
The next important step linking STICs with serous
ovarian carcinoma was the observation that 35-70% of
sporadic ovarian and peritoneal HG-SCs showed muco-
sal tubal involvement, including STICs. Kindelberger et
al extensively examined the fallopian tubes from 55 con-
secutive cases of serous carcinoma [28]. They showed
that over 70% of serous carcinomas involved the endo-
salpinx and approximately half contained STICs. To
further confirm the shared origin of these ovarian serous
carcinomas with their coexisting STICs, they also ana-
lyzed TP53 mutations in both sites from five cases.
Identical mutations were detected in both sites for all
cases. Salvador et al studied 12 cases of high-grade ser-
ous carcinoma, of which 10 cases showed either unilat-
eral tubal mucosal involvement by STICs (7/12, 58.3%)
or tubal obliteration ipsilateral to the dominant ovarian
mass (3/12, 25%) [39]. Further analysis of chromosomal
copy number changes by FISH demonstrated similar
results in 3 of 5 cases comparing ovarian serous tumors
with synchronous fallopian tube serous carcinoma, pro-
viding some additional support for a common, monoclo-
nal origin. Another study from the same group
examined 45 cases of primary peritoneal serous carci-
noma and found that 9 out of 26 cases (34.6%) with
incomplete tubal sampling and 9 out of 19 cases (47.4%)
that underwent complete examination of the tube had
STIC [29]. The above observations and similar other
studies, gave support to the proposal that STICs, which
almost always were detected in the fimbria, may be the
source of HG-SCs in both BRCA mutation carriers as
well as women who do not have a known genetic pre-
disposition for ovarian cancer. Finally, the spectrum of
putative and possibly non-obligate precursor lesions that
have been described in the fallopian tube lends addi-
tional support to the concept that the serous neoplastic
process may well begin in the fallopian tube rather than
ovary.
There are some potential limitations to the tubal the-
ory. First, a significant subset of HG-SCs is not asso-
ciated with STIC even after extensive sectioning of the
tube [40]. Second, HG-SCs occasionally arise from ser-
ous borderline tumors and LG-SCs [41,42]. Third, the
fimbria of the fallopian tube is normally in close contact
with the ovarian surface at the time of ovulation. It is
conceivable that when OSE is disrupted at the time of
ovulation, normal tubal epithelial cells from the fimbria
may be dislodged and implant in the ovary to form
OEIs (also called endosalpingiosis) [43]. Therefore, some
HG-SCs may develop from OEIs [44-46]. However,
although a proportion of adnexal HG-SCs may not
involve the fallopian tube, this does not necessarily rule
out a fallopian tube origin for these cases. An alternative
explanation for STICs that are seen in the non-BRCA
setting is that they represent random growth on the
tubal surface from an adjacent ovarian HG-SC. Again,
this possibility is mitigated by the fact that STIC is well-
established in the tube, but none have been described in
the ovary. Thus, the preponderance of available evidence
supports the tubal theory that a significant subset, and
possibly all HG-SCs originate from the fallopian tube.
Cellular evidence
The normal epithelium of the fallopian tubes is com-
prised of two cell types: ciliated and secretory. STICs
and their malignant invasive counterpart in the fallopian
tube, as well as HG-SCs, are all comprised of only secre-
tory cells, while the normal fallopian tube epithelium is
comprised of an admixture of ciliated and secretory
cells. Initial benign appearing secretory cell prolifera-
tions can be frequently identified in the fallopian tubes
Li et al. Journal of Hematology & Oncology 2012, 5:8
http://www.jhoonline.org/content/5/1/8
Page 3 of 11
with BRCA mutations or serous carcinomas, either asso-
ciated with p53 alterations (so-called p53 signatures), or
found with other genetic alterations in the absence of
alterations in p53 (secretory cell outgrowths or
SCOUTs).
p53 signatures
As defined by the Crum group, a p53 signature is a seg-
ment of benign appearing epithelium showing p53
immunoreactivity in at least 12 secretory cells. These
secretory cells can be contiguous or interrupted by some
remaining ciliated cells, but the lesion should have a low
proliferative index, as measured by MIB-1 staining (<
20%). This lesion is suggestive of early clonal expansion
but falls short of a bona fide neoplastic proliferation.
In a study by Lee et al, p53 signatures were observed
in 37% and 33% of women with and without BRCA
mutations respectively. p53 signature (53%) was more
frequently identified in fallopian tubes harboring STICs.
p53 signature shares several attributes with STIC,
including: 1) fimbrial location in > 80%; 2) intense p53
immunoreactivity; 3) involvement of the secretory cell;
4) evidence of DNA damage as manifested by punctuate
immunopositivity for g-H2AX; 5) TP53 mutations in
approximately 60%; 6) identical TP53 mutations with
concurrent STIC lesions; 7) occasionally, direct continu-
ity with STIC. The presence of p53 signature in the fim-
bria of normal women provides evidence that suggests
that secretory cells can experience sufficient toxic
damage to trigger a DNA damage response under nor-
mal physiologic conditions [10]. To determine whether
the same lesions also occur in the ovarian epithelium or
cortical inclusions, Folkins et al examined the ovaries of
75 BRCA mutation carriers, only one OSE showed p53
signature and none in cortical inclusions, confirming
that p53 signatures preferentially arise in fallopian tube
epithelium rather than OSE [47]. Based on these find-
ings, a sequence of pathogenetic events has been pro-
posed that under some genotoxic events, secretory cells
are prone to DNA damage, followed by TP53 mutation
and progressive loss of cell cycle control, which eventu-
ate in the development of carcinoma.
The frequency of p53 signatures in women with and
without BRCA mutations is nearly the same, suggesting
that p53 signature is not directly linked to this genetic
risk factor [10]. It is presumed that p53 signatures rarely
undergoes transition from benign to malignancy in
women who do not have a BRCA mutation, consistent
with its role as a latent precursor, which, by definition,
requires an additional event to undergo this transition.
In contrast, it is hypothesized that for the women who
have BRCA mutations, they are particularly susceptible
to subsequent events, such as loss of BRCA1 or BRCA2
function since they have had a preexisting germline
mutation.
Secretory cell outgrowth
More recently, the spectrum of potential precursors in
the fallopian tube was expanded to include more secre-
tory cell proliferations, which was defined as secretory
cell outgrowth (SCOUT) [48,49]. SCOUT is defined as a
discrete expansion of at least 30 epithelial cells of secre-
tory type (BCL2 expressing, p73 non-existing) that are
distinct against a heterogeneous background of tubal
secretory and ciliated cells [49]. A p53 signature is
essentially a p53-positive SCOUT with different size
requirements. SCOUTs have other characteristics that
distinguish them from p53 signatures, including 1) sig-
nificantly wider and more even distribution between
fimbrial and proximal areas of the fallopian tube; 2) loss
or reduction of PAX2 expression (so-called PAX2-null
SCOUTs); 3) Lack of alterations in TP53 or diffuse
DNA damage [49]. Some studies investigated the fre-
quency of SCOUTs using the patterns of BCL2/p73
immunostaining in tubes from women with serous car-
cinoma, inherited mutations in BRCA1 or BRCA2 and
benign controls [49]. SCOUTs were found to be signifi-
cantly more prevalent in the serous carcinoma group
and more aging patients as compared to the others
[48,49]. Abnormalities in both p53 and PAX2 expression
occurred in the distal fallopian tube and characterized
p53 signatures, STICs and advanced pelvic serous carci-
nomas. All three entities can, on occasion, be demon-
strated in continuity, and may share identical TP53
mutations and loss of PAX2 staining [49]. These find-
ings indicate that PAX2 dysfunction is involved in HG-
SC development. However, only a few SCOUTs with
both abnormal p53 and PAX2 expression (p53 signa-
tures) are linked firmly enough to pelvic serous cancers
to be confirmatory of a causal relationship. Thus, future
research will be required to establish whether SCOUTs
are reactive or precancerous.
Molecular evidence
The TP53 gene is mutated in almost 100% of HG-SC
[50,51]. This mutation is not only nearly ubiquitous in
HG-SC, but is also an early event in HG-SC carcinogen-
esis. Intense p53 immunoreactivity and TP53 gene
mutations have been observed in STICs, and half of p53
signatures display TP53 mutations [10,28,29,47]. In
some cases p53 signatures and STICs share identical
TP53 mutations with the concomitant HG-SC, suggest-
ing a clonal relationship between them [10,28]. Further
evidence implicating the fallopian tube as the site of ori-
gin comes from a gene expression profiling studies,
showing that the gene expression profile of HG-SC is
more closely related to the fallopian tube than to the
OSE [52,53]. Based on the above evidence, a plausible
serous carcinogenic model has emerged following a
spectrum of visible epithelial alterations with the
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following stages: p53 signature, tubal lesions in transi-
tion (tubal dysplasia), STIC, and the full blown serous
carcinoma.
The tubal theory: the fallopian tube as the site of
origin for “ovarian” low grade serous carcinoma
LG-SC is thought to evolve in a stepwise fashion from
OEIs/serous cystadenomas to serous borderline tumors
to invasive carcinoma [54,55]. Our group recently
showed that the majority of OEIs are derived from the
fallopian tube rather than OSE, and that the tubal secre-
tory cell is the likely the cell origin of LG-SC [56]. This
central role of the fallopian tube in various components
of this sequence has received further evidentiary support
from other groups [57,58].
Clinical-pathological evidence
Development of LG-SC in a step-wise fashion from
OEIs is supported by the following morphologic obser-
vations. First, the majority of serous cystadenomas are
thought to be derived from OEIs, as both display a mor-
phologically and immunophenotypically similar epithe-
lial lining, and the diagnostic criterion separating OEIs
from serous cystadenoma is arbitrarily made at the 1 cm
size threshold [59]. Second, the majority of LG-SCs are
associated with borderline tumors [15] and histological
transitions from serous cystadenomas to borderline
tumors are observed in nearly 75% of cases [60]. Third,
foci of true early invasion in serous borderline tumors
resemble LG-SC [60-63]. Additionally, several studies
have shown that micropapillary serous borderline
tumors have a higher frequency of invasive implants as
compared with typical serous borderline tumors, and
those implants are histologically identical to LG-SC
[64,65]. All these morphologic observations support a
model wherein LG-SC evolves from OEIs/serous cysta-
denomas via a serous borderline tumor.
Cellular evidence
Since OEI may represent an initial lesion in the process
of LG-SC development, demonstration of OEI origina-
tion may provide insights into the origin of LG-SC.
Recently, our group evaluated the morphologic and
immunophenotypic features of OEIs, OSE, serous
tumors (cystadenomas, borderline tumors, LG-SCs), and
distal tubal epithelium to gain a significant insight into
the origin of LG-SCs [56]. In our study, we found there
were two types of OSE. The vast majority OSE displayed
a mesothelial phenotype (calretinin+/PAX8-/tubulin-)
and a low proliferative index (0, 12 per 1000), while
about 4% of cases displayed foci with tubal phenotype
(calretinin-/PAX8+/tubulin+). Although the epithelium
with tubal phenotype was only found in 4% cases, it did
show that benign tubal epithelia are able to implant on
the ovarian surface and architecturally simulate ‘OSE’
microscopically. In contrast, there were also two types
of OEIs, while their proportional distributions were sig-
nificantly different from those of OSE. Most (78%) of
the OEIs displayed a tubal phenotype and had a signifi-
cantly higher proliferative index than OSE, indicating
that in most cases, OSE and OEIs are of different cellu-
lar lineages. The fact that we found more tubal-like
epithelium in OEIs than in OSE is a strong argument in
support of the notion that most OEIs are not derived
from the OSE. The most straightforward explanation is
the fallopian-derived OEIs represent intraovarian endo-
salpingiosis, which is well in line with the ideas
expressed by Dubeau and Crum [30,66]. Furthermore, if
the fallopian tube-derived OEIs (78%) were truly origi-
nating from mesothelium-derived OEIs through a mül-
lerian metaplasia, the metaplastic process must be a
common event and hybrid type of OEIs should be com-
monly found in the ovary. However, the fact that the
hybrid or intermediate type of OEIs with both mesothe-
lial and tubal phenotypes were rarely found makes
another argument that mesothelium-derived OEIs
undergoing metaplasia to fallopian tube-like OEIs is
unlikely. In addition, mesothelium-derived OEIs seem
not able to grow into a tumor mass as all these OEIs
have an extremely low cellular proliferative index (simi-
lar to OSE), while fallopian-derived OEIs showed com-
parable proliferative activity and immuophenotypes that
are similar or identical to ovarian serous tumors. From
these findings, we believe that the tubal derived OEIs
are likely originated from tubal epithelia, and are the
likely precursors of serous cystadenomas, borderline
tumors and LG-SCs, respectively.
We also studied the proportional distribution of
ciliated cells from OEI/cystadenomas to borderline
tumors to LG-SCs, and found that there was a progres-
sive decrease in the population of ciliated cells as evi-
denced by increasing secretory/ciliated cell ratio. This
suggested that LG-SCs are consequences of a clonal
expansion of tubal secretory cells, as is likely in high-
grade serous carcinogenesis.
Other groups also linked the LG-SC to the fallopian
tube in their recent studies. Kurman et al recently iden-
tified a fallopian tube lesion, designated as “papillary
tubal hyperplasia” (PTH) and defined as “tubal prolifera-
tions that exhibited papillary tufting and detached clus-
ters of bland epithelium frequently, but not always,
associated with psammona bodies”. The clusters of
“epithelial cells and small papillae were found floating in
the lumen or protruding from the tubal mucosa into the
lumen” [57]. On the basis of the findings in their study,
they proposed a model for the origin and development
of the spectrum of pelvic low-grade serous prolifera-
tions. The process begins with chronic inflammation,
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leading to tubal hyperplasia, which, if it progresses to
PTH, can shed and implant tubal epithelium on ovarian
and peritoneal surfaces, resulting in a variety of low-
grade serous proliferations including serous borderline
tumors, noninvasive epithelial implants, and endosalpin-
giosis. Another study by Laury et al showed that PAX2-
null SCOUTs were more frequently found in the fallo-
pian tube of women with serous borderline tumors and
the loss of PAX2 expression occurred in most serous
borderline tumors [58]. In particular, they identified two
cases with discrete multifocal papillary SCOUTs in the
fallopian tubes, which they thought were associated with
serous borderline tumors. This lesion is similar to the
PTH described by Kurman’s group. However, we feel it
is too premature to suggest PTH as the true precursor
for LG-SC. First, OEIs were widely accepted as the ori-
gin of LG-SC, which usually presented with a mixed of
ciliated and secretory cell rather than pure secretory cell
proliferation [56]. Second, this kind of papillary prolif-
eration is rarely found in the fallopian tube in our prac-
tice, which is disproportional to the frequency of LG-
SCs. Third, if PTH implanting on the ovarian surface is
common, the subsequent LG-SC should be more com-
monly presenting as exophytic tumors rather than endo-
phytic. In reality, it is rarely to see exophytic LG-SC in
pathology practice. Therefore, based on our understand-
ing, it is unlikely that PTH serves as the main precursor
source for LG-SC.
Carcinogenesis of ovarian serous carcinoma
Molecular carcinogenesis of HG-SC
Recently published findings from the Cancer Genome
Atlas (TCGA) project confirmed previously reported
findings and provided significant new insights into the
molecular events that underlie HG-SC [67]. In that
study, the authors analyzed mRNA expression, miRNA
expression, promoter methylation, and DNA copy num-
ber in 489 HG-SCs, as well as the coding genes in 316
tumors. HG-SC displays a remarkably high degree of
genomic disarray, with 113 significant focal DNA copy
number aberrations, and promoter methylation events
involving 168 genes. The principal molecular events
involving HG-SCs involve the TP53, BRCA1 and BRCA2
genes. Mutations in TP53 were seen in at least 96% of
cases, and BRCA1/2 alterations were seen in 22% of
tumors due to a combination of germline and somatic
mutations. Six other statistically recurrently mutated
genes were identified, including RB1, NF1, FAT3,
CSMD3, GABRA6, and CDK12, but only in less than 6%
of cases.
In general, most of the mutations in TP53 are frame-
shift or nonsense mutations that increase the stability of
the altered and truncated protein, leading to accumula-
tion detectable by immunohistochemistry. However, the
mutations are sometimes insertions, deletions, or stop
codons leading to lack of p53 production. Intense p53
staining and TP53 mutations have been observed in p53
signatures and STIC of fallopian tubes [10,28,29,47,68].
Thus, to date, TP53 is the earliest change that has been
associated with HG-SC precursor lesions, and appears
to be an obligatory, as well as early event for HG-SC.
Interestingly, an increased risk of ovarian cancer is not
associated with Li-Fraumeni syndrome (where TP53
mutations are characteristic), especially considering that
p53 signatures foci in distal fallopian tube are much
more numerous in patients with Li-Fraumeni syndrome
[69]. In contrast, there is little, if any, difference in the
frequency of p53 signatures in BRCA mutation carriers
versus non-carriers [10], which suggest that although
TP53 mutations are necessary in the genesis of HG-SC,
they are not sufficient to trigger a sequence of neoplasia.
The BRCA genes encode nuclear proteins that partici-
pate in DNA repair via non-error prone homologous
recombination [70]. BRCA1 or BRCA2 gene mutations
represent a high-risk factor for HG-SC, and women har-
boring such mutations have a 30% to 70% chance of
developing ovarian cancer by the age of 70 [71]. This
mutation usually occurs in hereditary HG-SC cases and
the frequency of germline BRCA1 or BRCA2 mutation is
as high as 18% in population-based cohorts of women
with serous carcinoma. As previously noted, up to 22%
of HG-SC have germline or somatic mutations in
BRCA1/2. Approximately 11% of HG-SCs have lost
BRCA1 expression through DNA hypermethylation, and
that epigenetic silencing of BRCA1 is mutually exclusive
of either BRCA1 or BRCA2 mutations [67]. Only one-
wild allele of BRCA1 or BRCA2 is sufficient for DNA
repair mechanism, and additional somatic loss of the
wild-type allele is needed in the development of carci-
noma in women with germline BRCA mutations. Many
studies have found such LOH of BRCA in early ovarian
serous carcinoma, STIC, and even in some OEIs/OSE in
ovaries from prophylactic oophorectomy specimens,
indicating that loss of BRCA function is an early event
in HG-SCs [72-74].
TP53 mutations and BRCA1/BRCA2 inactivations are
both early events in HG-SCs, and the specific carcinoge-
netic sequence of these gene alterations is becoming
clearer. p53 signature is common in women with and
without inherited mutations in BRCA1 or BRCA2
[10,47]. On the other hand, in a small series of STIC
and p53 signatures analyzed in women with germline
BRCA1 mutations, loss of the wide-type BRCA1 allele
was observed in STIC but not in the p53 signature foci
[74]. These findings indicate that loss of BRCA1 and/or
BRCA2 function is not necessary for p53 signature’s for-
mation and is presumed a later event than TP53 muta-
tion. Knudson’s classic 2-hit hypothesis appears to be
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operational. For example, despite the abundance of
TP53 mutations in LFS, inactivation of a second critical
gene- such as BRCA- is not more likely to occur in this
syndrome, leading to a similar frequency of ovarian can-
cer therein with that of the general population [69].
Finally, all HG-SCs, including the very earliest tumors
show high levels of allelic imbalance [75]. Genome-wide
analysis of DNA copy number alterations has demon-
strated significant numbers of amplifications and dele-
tions, among which the alterations in cyclin E1, AKT2,
Notch3, PIK3CA, c-Myc, RB1, CDKN2A/B, CDK12,
CSMD1, CSMD3, DOCK4, NF1, FAT3, GABRA6 are
most common [67,76,77]. The main molecular changes
are summarized in Figure 1.
Molecular carcinogenesis of LG-SC
Genetically, LG-SCs are relatively stable and typically
display a variety of mutations related to specific signal-
ing pathways, including KRAS or BRAF but very rarely
TP53. One study found KRAS mutations at codons 12
and 13 in 35% of LG-SCs and in 33% of borderline
tumors [78]. Similarly, BRAF mutations at codon 599
were seen in 30% of LG-SC and 28% of serous border-
line tumors [78]. In addition, a 12-base-pair insertion
mutation of ERBB2 (encoding HER2/neu), which acti-
vates an upstream regulator of KRAS, has been detected
in 9% of these tumors [79]. It is of interest that muta-
tions of these three genes are mutually exclusive [80,81].
Thus, more than 60% of LG-SCs and borderline tumors
have mutations of KRAS, BRAF or ERBB2. Furthermore,
KRAS or BRAF mutations can be detected even in
benign cystadenomas, indicating they are early events in
the carcinogenesis of LG-SC [13]. Constitutive MAPK
signaling will in turn lead to uncontrolled proliferation.
Global gene profiling analysis showed that LG-SC had
several allelic imbalances on multiple chromosomal
arms, such as chromosomes 1p, 5q, 8p, 18q, 22q, and
Xp, and gradually increasing chromosomal instability
often presents from serous borderline tumor to border-
line tumor with micropapillary structures to LG-SC
[75,82], although not at comparable levels to HG-SC
(Figure 1).
TP53 Gene Mutation BRCA1/2 Gene Function Loss DNA Copy Number Amplification and Deletion
Tubal Epithelium LG-SCBorderlineserous tumor
Benign serous 
cystadenomaOEI
KRAS/BRAF/ERBB2 Gene Mutation and secretory cell expansion                    
1pǃ5qǃ8pǃ18qǃ
22qঞXp
Allelic ImbalanceLow-Grade Serous Carcinoma










Figure 1 Molecular changes of serous carcinogenesis. Ovarian low-grade serous carcinoma (LG-SC) development starts from tubal epithelia,
which invaginate into ovarian stroma to form ovarian epithelial inclusions (OEI). Further growth of OEI forms serous cystadenoma, serous
borderline tumor, and LG-SC in a step-wise fashion. The most common molecular changes including KRAS, BRAF, or ERBB2 mutations are
increased in this process as indicated in the upper panel. Chromosomal changes are more common prior to the development of LG-SC. In
contrast to LG-SC, high-grade serous carcinoma (HG-SC) develops in a different pathway. It starts from tubal epithelia, then develop into latent
precancer (p53 signature), precancer (tubal dysplasia), early cancer (serous intraepithelial carcinoma, STIC), and to full blown HG-SC. Within this
process, the earliest molecular change is p53 gene mutation as indicated in the low panel. Other molecular changes are included in the figure,
too. There are about 10% or less LG-SCs which can develop into HG-SC upon acquiring p53 mutation.
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Carcinogenetic model of ovarian serous carcinoma
The following model for female adnexal serous carcino-
genesis is supported by the currently available evidence:
Both low- and high-grade serous carcinomas likely origi-
nate from the secretory cells of the fallopian tube. These
secretory cell proliferations probably give rise to differ-
ent types of ovarian serous carcinomas along different
molecular pathways. First, under some exogenous and
endogenous toxic factors, secretory cells may start to
develop DNA damage. Accumulations of DNA damage
will lead to chromosomal instability and a series of
genetic alterations. TP53 mutation is an early event,
which may result in clonal alterations that is the latent
precursor, p53 signature. Only a subset of p53 signa-
tures undergoes subsequent molecular events such as
loss of BRCA function to transform to the malignant
lesion STIC. Additional DNA copy number changes also
play an important role in the development of malig-
nancy. These STIC lesions form papillary tufts and the
constituent cells are loosely cohesive, are easy to shed
and may implant on the surface of the ovary and the
peritoneum in the absence of invasive growth in the fal-
lopian tube. This is the main carcinogenetic pathway of
HG-SC. Second, the normal fallopian tubal epithelium,
mostly from fimbriated end, can easily implant on the
ovarian surface. Two possibilities exist for how this
detachment and implantation occurs: 1) Given the close
spatial relationship between the ovarian surface and the
tubal fimbriated end, ovulation or non-ovulation
induced disruption of the ovarian surface, may offer an
opportunity for the adjacent tubal epithelium to detach
and implant in the ovarian stroma [43] and 2) Adhesion
of tubal epithelium on the ovarian surface, from inflam-
mation or other factors, and ongoing stromal growth
around it may eventuate in fallopian tube derived-OEI
formation. The acquisition of KRAS or BRAF and possi-
bly other mutations in tubal derived OEIs and serous
cystadenomas result in their transformation to serous
borderline tumors and ultimately, LG-SC [78,80,83-85].
Third, a small proportion of HG-SC may develop from
LG-SC after the acquisition of additional mutations
such as TP53 [43]. Fourth, occasionally some tube-
derived-OEIs acquire TP53 gene mutations and develop
to HG-SCs, which has been seen in women with BRCA
mutations [46]. The latter two pathways may explain
why in some HG-SCs there is neither evidence of tubal
involvement nor STIC lesions. The overall ovarian ser-
ous carcinogenetic model is illustrated in Figure 2.
Clinical implications
Previous attempts at screening for ovarian cancer, in the
hope of, at minimum, intercepting the development of
the disease at an early stage, have largely been unsuc-
cessful. In one large multi-institutional prospective study
of 35000 women screened with CA-125 and transvaginal
ultrasounds, 70% of the women presented with advanced
stage disease, which was no different from unscreened
populations [86]. This suggests that cancer prevention
should probably play a larger role if there is to be suc-
cess in reducing ovarian-cancer related mortality.
If the fallopian tube is considered the site of origin for
most adnexal serous carcinomas, then preventive strate-
gies rather than therapeutics including immunotherapy
[87], such as salpingectomies, become much more rea-
listic. Sparing the fallopian tubes during hysterectomy
for benign uterine indications provides no known phy-
siological benefits, as the remaining tubes are completely
devoid of any function in the aftermath of such a proce-
dure, and the patient hormone profile is not altered by
salpingectomy, even several months after surgery [88].
Thus, simultaneous risk-reducing salpingectomies may
become more widespread whenever a hysterectomy
needs to be performed for benign indications. If adnexal
serous carcinomas are unequivocally shown to develop
almost exclusively in the fimbria, salpingectomy alone
would be sufficient to reduce the risk of adnexal serous















Figure 2 “Ovarian” serous carcinogenesis. The most common
site of the fallopian tube for serous cancer development is the
tubal fimbriated end (TFE). Benign tubal epithelia (BTE) are able to
form ovarian epithelial inclusions (OEI) through an unclear pathway,
then follow low-grade serous carcinoma (LG-SC) development
pathway. Within this pathway, there are small amount of OEIs which
are derived from ovarian surface epithelia (OSE). It is currently
believed that these OSE derived OEIs are barely able to form LG-
SCs. In contrast to LG-SC, HG-SC mainly derives from serous tubal
intraepithelial carcinoma (STIC), which is able to stick on ovarian
surface or get into ovarian stroma and expand to form full blown
cancer. There are about 10% or less LG-SCs which can develop into
HG-SC upon acquiring p53 mutation.
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of these issues will likely need long term prospective
trials comparing the prevalence of adnexal serous can-
cers between women who underwent total salpingecomy
procedures and women who did not.
Conclusion
Recent morphologic and molecular genetic studies have
led to a paradigm shift in our conceptualization of the
carcinogenesis and histogenesis of pelvic (non-uterine)
serous carcinomas. It appears that both LG-SC and HG-
SC originate from the fallopian tube. Clonal expansions
of the tubal secretory cell probably give rise to both
low- and high-grade serous carcinomas, and the degree
of ciliated conversion is a function of the degree to
which the genetic hits deregulate normal differentiation.
This new paradigm has profound clinical implications in
ovarian cancer prevention strategies.
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